Skip to main content
. 2023 Mar 28;26(4):106506. doi: 10.1016/j.isci.2023.106506

Table 5.

Median [IQR antibody (IgG BAU/ml) to receptor-binding domain (RBD) by self-reported reactogenicity to second vaccine dose

Mild or No reactogenicity Moderate to severe reactogenicity Pa
30–50 Cohort
 N 47 220
 2 Weeks Post 2nd Dose 4927 [1841, 6167] 5298 [2996, 8305] 0.11
 12 Weeks Post 2nd Dose 485 [233, 857] 712 [406, 1376] 0.0054
 24 Weeks Post 2nd Dose 196 [109, 241] 278 [182, 633] 0.0064
 48 Weeks Post 2nd Dose 1033 [474, 3830] 1250 [465, 3941] 0.91
70+ Cohort
 N 421 269
 2 Weeks Post 2nd Dose 1834 [757, 3635] 2874 [1156, 5660] 0.00012
 12 Weeks Post 2nd Dose 342 [162, 832] 545 [251, 1134] <0.0001
 24 Weeks Post 2nd Dose 177 [92, 415] 250 [136, 689] <0.0001
 48 Weeks Post 2nd Dose 2484 [840, 6658] 2674 [753, 5916] 0.84

IQR, interquartile range; RBD, receptor-binding domain; BAU, binding antibody units.

a

p values are from Kruskal-Wallis tests.